Pinoresinol Diglucoside

Synonyms: 松脂醇二葡萄糖苷
Pinoresinol Diglucoside 是一种具有口服活性的木脂素,具备多功能生物活性,可与 ALB、HIF1A、GSK3B、BCL2、MARK3、IL6、NF-κB p65、Nrf2、HO-1 和 TLR4 等靶点相互作用,并调控 PI3K-Akt、雌激素、MAPK、Rap1、AKT/mTOR/NF-κB 以及 TGF-β1/Smads 等信号通路,从而调节成骨作用、骨吸收、氧化应激、炎症、细胞凋亡、铁死亡、铁蛋白自噬、心肌纤维化和血管舒张,可用于骨质疏松症、缺血/再灌注诱导的脑损伤、阿尔茨海默病、心肌缺血再灌注损伤、软骨发育不良、糖尿病心肌病、心肌肥厚、高血压、顺铂诱导的听力损失、动脉粥样硬化性心血管疾病以及废用性骨质疏松症的相关研究。
产品编号: MS-Q97935 纯度: 99.84% CAS No.: 63902-38-5 分子式: C32H42O16 分子量: 682.67
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Pinoresinol Diglucoside 是一种具有口服活性的木脂素,具备多功能生物活性,可与 ALB、HIF1A、GSK3B、BCL2、MARK3、IL6、NF-κB p65、Nrf2、HO-1 和 TLR4 等靶点相互作用,并调控 PI3K-Akt、雌激素、MAPK、Rap1、AKT/mTOR/NF-κB 以及 TGF-β1/Smads 等信号通路,从而调节成骨作用、骨吸收、氧化应激、炎症、细胞凋亡、铁死亡、铁蛋白自噬、心肌纤维化和血管舒张,可用于骨质疏松症、缺血/再灌注诱导的脑损伤、阿尔茨海默病、心肌缺血再灌注损伤、软骨发育不良、糖尿病心肌病、心肌肥厚、高血压、顺铂诱导的听力损失、动脉粥样硬化性心血管疾病以及废用性骨质疏松症的相关研究。

生物实验数据

生物活性 Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivities that interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and regulates signaling pathways such as PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads, thereby modulating osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, myocardial fibrosis, and vasodilation, and can be used in research related to osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer's disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular disease, and disuse osteoporosis.
体外研究
(In Vitro)

Pinoresinol diglucoside (20-80 μM) 可抑制 RANKL 诱导的 RAW264.7 细胞向破骨细胞分化。
Pinoresinol diglucoside (20-80 μM; 3 days) 可破坏经 RANKL 诱导分化的 RAW264.7 破骨细胞中 F-actin 环的形成,在 80 μM 浓度下可实现完全破坏。
Pinoresinol diglucoside (20-80 μM; 3 days) 可抑制经 RANKL 诱导分化的 RAW264.7 细胞中破骨细胞分化相关蛋白 NFATc1、c-Fos、CTSK 和 TRAP 的表达。
Pinoresinol diglucoside (20-80 μM; 3 days) 可抑制经 RANKL 处理的 RAW264.7 细胞中 NF-κB 和 AKT-GSK-3β 信号通路的激活。
Pinoresinol diglucoside (80 μM) 可抑制 RANKL 诱导的 RAW264.7 细胞中 p65 的核转位。
Pinoresinol Diglucoside 可通过恢复 SOD 活性、eNOS 表达及 NO 生成,缓解 oxLDL 诱导的人脐静脉内皮细胞功能障碍。
Pinoresinol diglucoside (1 μM) 可通过减轻氧化应激、降低细胞损伤标志物水平、抑制细胞凋亡、提升细胞活力、上调 miR-142-3p 及下调 HIF1AN,缓解缺氧/复灌诱导的 H9c2 心肌细胞损伤。
Pinoresinol diglucoside (1 μM) 对 H9c2 心肌细胞中缺氧/复灌诱导损伤的保护作用可被 miR-142-3p 过表达逆转,进而导致氧化应激水平升高、细胞损伤标志物增加、细胞凋亡加剧,同时细胞活力下降。
Pinoresinol diglucoside 可在计算机模拟条件下与斑马鱼 FZD2 和 FZD5 发生强相互作用,结合能分别为 -8.27 kcal/mol 和 -8.63 kcal/mol,提示其具有激活 Wnt 信号通路的潜力。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 24 h) 可通过下调 TGF-β1/Smads 信号通路,抑制高葡萄糖诱导的 H9c2 细胞心脏纤维化反应。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 48 h) 可抑制高糖诱导的人脐静脉内皮细胞 (HUVECs) 内皮间质转化 (EndMT)。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 48 h) 可抑制外源性 TGF-β1 诱导的人脐静脉内皮细胞 (HUVECs) 内皮间质转化 (EndMT)。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 48 h) 对高糖诱导的人脐静脉内皮细胞 (HUVECs) 内皮间质转化 (EndMT) 的抑制作用会因 TGF-β1 敲低而消失,表明 PDG 通过 TGF-β1 通路发挥作用。
Pinoresinol diglucoside (25 μM; 24 h) 可维持 HEI-OC1 细胞的活力,单独作用时不会诱导氧化应激,还能减轻 Cisplatin 诱导的 HEI-OC1 细胞氧化应激与细胞死亡。
Pinoresinol diglucoside (25 μM; 24 h) 可在体外新生小鼠基底膜中下调 SOCS1 蛋白的表达,并减弱 Cisplatin 诱导的该基底膜中 SOCS1 的上调。
Pinoresinol Diglucoside (PDG) (2.5-7.5 μg/mL; 2 h pre-incubation, 24 h with ISO stimulation) 可通过下调肥大生物标志物和促炎细胞因子的 mRNA 表达,抑制异丙肾上腺素诱导的新生大鼠心室心肌细胞肥大与炎症反应。
Pinoresinol Diglucoside (PDG) (2.5-7.5 μg/mL; 24 h with PE stimulation) 可抑制去氧肾上腺素诱导的新生大鼠心室肌细胞中 AKT/mTOR/NF-κB 信号通路激活,降低心肌肥大相关蛋白的表达。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 24 h) 可抑制高糖诱导的纤维化反应,并下调 H9c2 细胞中的 TGF-β1/Smads 信号通路。
Pinoresinol Diglucoside (2.5-7.5 μg/mL; 48 h) 可抑制高糖诱导的人脐静脉内皮细胞 (HUVECs) 内皮间质转化 (EndMT)。
Pinoresinol diglucoside (0.1-1 μM; 60 min pre-incubation + 24 h co-treatment with oxLDL, or 24 h alone) 可抑制 oxLDL 诱导的人脐静脉内皮细胞 (HUVECs) 凋亡,其中 1 μM 可完全消除该凋亡效应,0.1 μM 可将凋亡细胞比例降至 17.2%。
Pinoresinol diglucoside (1 μM; 60 min pre-incubation + 24 h co-treatment with oxLDL, or 24 h alone) 可减轻 oxLDL 诱导的人脐静脉内皮细胞 (HUVECs) 中活性氧 (ROS) 和 MDA 的产生,与仅用 oxLDL 处理的细胞相比,可使 ROS 水平降低 20% 以上。
Pinoresinol diglucoside (1 μM; 60 min pre-incubation + 24 h co-treatment with oxLDL, or 24 h alone) 可逆转 oxLDL 对人脐静脉内皮细胞 (HUVECs) 总 SOD 活性的抑制作用,使其活性恢复至接近对照组水平。
Pinoresinol diglucoside (1 μM; 60 min pre-incubation + 24 h co-treatment with oxLDL, or 24 h alone) 可缓解 oxLDL 对 HUVEC 中 NO 生成及 eNOS mRNA 表达的抑制作用,使这两项指标完全恢复至对照组水平。
Pinoresinol diglucoside (1 μM; 60 min pre-incubation + 24 h co-treatment with oxLDL, or 24 h alone) 可抑制 oxLDL 诱导的人脐静脉内皮细胞 (HUVECs) 中 LOX-1、ICAM-1 和 NF-κB 的 mRNA 及蛋白表达上调,基本消除 oxLDL 所导致的 1.7 至 3.5 倍表达升高。
Pinoresinol diglucoside (1 μM; 60 min pre-incubation + 45 min co-treatment with oxLDL, or 45 min alone) 可通过降低 p38MAPK 和 NF-κB p65 的磷酸化水平,抑制 oxLDL 诱导的人脐静脉内皮细胞 (HUVECs) 中 p38MAPK/NF-κB 信号通路的激活。
Pinoresinol diglucoside (PG2) (1 μg/mL; 30 min at 38°C) 在无细胞抗炎实验中可抑制 80.0%的 β-葡萄糖醛酸苷酶活性。
Pinoresinol diglucoside (PG2) (1-1000 μM; 10 min) 在无细胞实验中清除 DPPH 自由基的 IC50 为 600 μM,且活性随浓度升高而增强。
Pinoresinol diglucoside (10 nM-10 μM; 3 days) 在 1 μM 浓度下可最大程度促进新生小鼠颅盖骨成骨细胞的成骨分化,该效果通过处理 3 天后的 ALP 活性检测得出。
Pinoresinol diglucoside (1 μM; 12-hour SMG exposure for proliferation, apoptosis, oxidative stress, cell cycle assays; 6 days of daily 12-hour SMG exposure for osteogenic differentiation assays) 可保留模拟微重力环境下新生小鼠颅盖骨成骨细胞的成骨分化能力,降低氧化应激水平,促进细胞增殖,抑制细胞凋亡,并逆转 G0/G1 细胞周期阻滞。
Pinoresinol diglucoside (1 μM; 3 days) 可最大程度增强新生小鼠颅盖骨成骨细胞中碱性磷酸酶的活性,该酶是成骨分化的标志物。

Western Blot Analysis

Cell Line: RANKL-differentiated RAW264.7 cells
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 3 days
Result: Inhibited the expression of NFATc1, c-Fos, CTSK, and TRAP proteins significantly.

Western Blot Analysis

Cell Line: RAW264.7 cells
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 3 days
Result: Inhibited phosphorylation of IκBα, p65, AKT, and GSK-3β significantly, and inhibited degradation of IκBα.

Cell Viability Assay

Cell Line: House Ear Institute-Organ of Corti 1 (HEI-OC1)
Concentration: 25 μM; 30 μM (cisplatin, co-treatment)
Incubation Time: 24 h
Result: Resulted in a 95.8% cell survival rate when used alone.
Resulted in a 91.7% cell survival rate when co-treated with 30 μM cisplatin.
Did not alter intracellular or mitochondrial reactive oxygen species (ROS) levels relative to control when used alone.
Markedly reduced cisplatin-induced increases in DCFH-DA (intracellular ROS) and MitoSOX (mitochondrial superoxide) fluorescence when co-treated with cisplatin.
Restored cisplatin-reduced mitochondrial membrane potential (JC-1 aggregate/monomer ratio) when co-treated with cisplatin.

Apoptosis Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 0.1 μM (pre-incubated then co-treated with oxLDL); 1 μM (pre-incubated then co-treated with oxLDL); 1 μM (no oxLDL)
Incubation Time: 60 min pre-incubation + 24 h co-treatment with oxLDL; 24 h (no oxLDL)
Result: Reduced oxLDL-induced HUVEC apoptosis from 25.7% to 17.2%.
Abrogated oxLDL-induced HUVEC apoptosis.
Did not induce apoptosis when administered alone.

Western Blot Analysis

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 1 μM (pre-incubated then co-treated with oxLDL); 1 μM (no oxLDL)
Incubation Time: 60 min pre-incubation + 45 min co-treatment with oxLDL; 45 min (no oxLDL)
Result: Significantly inhibited oxLDL-induced phosphorylation of p38MAPK and NF-κB p65 in HUVECs.
Did not affect p38MAPK or NF-κB p65 phosphorylation when administered alone.
体内研究
(In Vivo)

Pinoresinol diglucoside (10 mg/kg/天;口服;每日给药;连续 3 天) 先发生去糖基化反应生成代谢物 M49,随后在体内发生呋喃环开环、去甲氧基化、葡萄糖醛酸化及硫酸化等代谢反应,并通过 BCL2、MARK3、GSK3B、HIF1A、ALB、IL6 等 146 个重叠的骨质疏松相关靶点,调控 PI3K-Akt 和雌激素信号通路,从而发挥潜在的抗骨质疏松作用。
Pinoresinol diglucoside (5-10 mg/kg;尾静脉注射;单次给药;MCAO 造模前 1 小时) 对小鼠 MCAO/R 诱导的脑损伤具有剂量依赖性神经保护作用,并可调控抗炎及抗氧化通路。
Pinoresinol Diglucoside (5-10 mg/kg;经尾静脉静脉注射;MCAO 前 1 小时单次给药) 可通过 NF-κB 通路抑制神经炎症、Nrf2/HO-1 通路增强抗氧化活性,呈剂量依赖性缓解雄性 C57BL/6 小鼠的 MCAO/R 诱导性脑损伤,且 10 mg/kg 剂量的保护作用优于 5 mg/kg 剂量。
Pinoresinol Diglucoside (灌胃,每日,连续 3 周,剂量 5-10 mg/kg) 可通过调控 TLR4/NF-κB 和 Nrf2/HO-1 通路,显著缓解雄性 BALB/c 小鼠中由 Aβ1-42 诱导的认知障碍、神经炎症、氧化应激及神经元凋亡。
Pinoresinol diglucoside (0.75-3 μM; exposure in culture medium; daily; 7 dpf to 9 dpf) 可通过增强骨矿化、纠正骨骼与软骨畸形、改善运动功能、上调成骨相关基因,以及通过与 FZD2 和 FZD5 受体相互作用激活 Wnt 信号通路,缓解地塞米松诱导的 Danio rerio (斑马鱼) 幼鱼骨质疏松症和软骨发育不良。
Pinoresinol diglucoside (1-5 mg/kg/天;腹腔注射;每日;8 周) 可通过下调 TGF-β1/Smads 信号通路,呈剂量依赖性地缓解 db/db 小鼠中糖尿病心肌病 (DCM) 诱导的心肌纤维化及内皮间质转化,其中 5 mg/kg/天的高剂量效果最为显著。
Pinoresinol diglucoside (25 mg/kg,腹腔注射,每日 1 次,与 Cisplatin 给药周期同步) 可通过保护耳蜗毛细胞存活、听觉功能及耳蜗内电位,同时通过下调 SOCS1 抑制铁死亡和 NCOA4 介导的铁蛋白自噬,显著减轻 Cisplatin 诱导的雄性 C57BL/6 小鼠耳毒性。
Pinoresinol Diglucoside (每日 2.5-7.5 mg/kg;腹腔注射;每日给药;持续 3 周) 可剂量依赖性地减轻雄性 Sprague Dawley 大鼠中由 AAC 诱导的心肌肥厚,其中每日 7.5 mg/kg 的剂量对心脏质量指数、肥厚生物标志物、纤维化、炎症以及 AKT/mTOR/NF-κB 信号通路的激活产生最显著的抑制作用。
Pinoresinol Diglucoside (每日 7.5 mg/kg;腹腔注射;每日给药;持续 3 周) 对健康雄性 Sprague Dawley 大鼠的心脏结构、肥大生物标志物、炎症反应或 AKT/mTOR/NF-κB 信号通路均无显著影响。
Pinoresinol diglucoside (1-5 mg/kg;腹腔注射;每日;8 周) 可通过下调 TGF-β1/Smads 信号通路抑制内皮-间充质转化,从而呈剂量依赖性缓解 db/db 小鼠中糖尿病心肌病诱导的心肌纤维化。
Pinoresinol Diglucoside (18-72 mg/kg;口服;每日;连续 21 天) 可有效对抗雄性 C57BL/6J 小鼠因后肢去负荷诱导的骨丢失,其中每日口服 18 mg/kg、连续 21 天的剂量对骨力学强度、矿化沉积率以及骨形成、骨吸收、氧化应激和炎症标志物的改善作用最为显著。
Pinoresinol Diglucoside (18-72 mg/kg;口服;每日一次;连续 21 天) 可有效对抗雄性 C57BL/6J 小鼠由后肢去负荷诱导的骨丢失,其中 18 mg/kg 剂量在恢复骨密度、微观结构、力学强度及骨代谢平衡方面展现出最优效力。
Pinoresinol Diglucoside (30-100 mg/kg;静脉注射;单次给药) 可在麻醉的自发性高血压大鼠中呈剂量依赖性地降低舒张压,降压幅度从 30 mg/kg 时的 25 mmHg 到 100 mg/kg 时的 120 mmHg 不等。

Animal Model: Sprague-Dawley (male, 6-8 weeks old, 200-220 g)
Dosage: 10 mg/kg/day
Administration: p.o.; daily; 3 days
Result: Identified or tentatively characterized 51 metabolites across rat biological samples: 9 in plasma, 28 in urine, 13 in feces, 10 in liver, 4 in heart, 3 in spleen, 11 in kidneys, and 5 in lungs.
Identified 146 overlapping targets between pinoresinol diglucoside/its metabolites and osteoporosis, including BCL2, MARK3, GSK3B, HIF1A, ALB, and IL6.
Enriched key pathways including the PI3K-Akt signaling pathway, estrogen signaling pathway, MAPK signaling pathway, and Rap1 signaling pathway.
Animal Model: C57BL/6 (male, 7-8 weeks old, 20-23 g, middle cerebral artery occlusion/reperfusion model)
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.v., caudal vein; single dose; 1 hour before MCAO induction
Result: Compared with the MCAO control group, the modified neurological severity score (mNSS) was significantly reduced, the infarct volume was significantly reduced to approximately 38%, brain water content was significantly reduced, and the number of intact neurons increased to approximately 40%.

Levels of TNF-α, IL-1β, IL-6, NO, ROS, and MDA in brain tissue were significantly decreased, while the activities of SOD, GSH, and GSH-Px were significantly increased.

Phosphorylation levels of IKKβ, IκBα, and p65 were significantly decreased, and p-p65 nuclear translocation was reduced.

Compared with the MCAO control group, the expression of NQO1, HO-1, and nuclear Nrf2 in brain tissue was significantly increased.
Animal Model: C57BL/6 (male, 7-8 weeks old, 20-23 g, middle cerebral artery occlusion/reperfusion model)
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.v. via caudal vein; single dose 1 h before MCAO
Result: Significantly reduced neurological deficit scores, brain infarct volume, and brain water content compared to MCAO controls.
Improved neuronal morphological structure (reduced pyknotic nuclei, reversed apoptotic neuron morphology) and increased intact neuron count.
Significantly decreased brain tissue levels of TNF-α, IL-1β, IL-6, NO, ROS, and MDA.
Significantly increased brain tissue activities of SOD, GSH, and GSH-Px.
Significantly inhibited NF-κB pathway activation (reduced phosphorylation ratios of IKKβ and IkBα, reduced nuclear p-p65 levels).
Significantly increased brain tissue HO-1 and NQO1 protein expression, and increased nuclear Nrf2 levels.
Produced greater magnitude of protective effects (reduced neurological deficit scores, brain infarct volume, brain water content; improved neuronal structure; decreased pro-inflammatory/oxidative markers; increased antioxidant activities; inhibited NF-κB pathway; enhanced Nrf2/HO-1 pathway) at 10 mg/kg compared to 5 mg/kg.
Animal Model: BALB/c (male, 3 months old, 20-25g, stereotactic hippocampal injection of Aβ1-42)
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.g.; daily; 3 weeks
Result: Reversed Aβ1-42-induced memory impairment, reducing escape latency in Morris water maze invisible platform trial, increasing percentage of time spent in target quadrant, and increasing number of target crossings.
Increased number of correct choices and reduced escape latency in Y-maze test.
Decreased brain tissue levels of proinflammatory cytokines TNF-α and IL-1β.
Reduced brain tissue levels of reactive oxygen species and malondialdehyde, and increased activity of antioxidant enzymes superoxide dismutase and catalase.
Upregulated the Bcl-2/Bax ratio, and downregulated expression of cleaved caspase-3 and cytochrome c in brain tissue, inhibiting neuronal apoptosis.
Reduced expression of TLR4 and activated NF-κB p65, and increased expression of Nrf2 and HO-1 in brain tissue.
All results were statistically significant (P < 0.05, P < 0.01, or P < 0.001 vs.
Aβ1-42 + vehicle group; n=10 per group).
Animal Model: db/db (8-week-old, 35-40g, spontaneous diabetic cardiomyopathy model); db/m (8-week-old, 18-20g, control)
Dosage: 1 mg/kg/day; 2.5 mg/kg/day; 5 mg/kg/day
Administration: i.p.; daily; 8 weeks
Result: Significantly inhibited collagen fiber deposition in cardiac interstitial and perivascular areas in a dose-dependent manner, with the high-dose group showing the greatest reduction in fibrosis area.
Reversed the upregulation of fibrotic marker mRNA levels (Col1a1, Col3a1, Postn) in a dose-dependent manner, with the high-dose group showing the most significant suppression.
Restored the mRNA levels of endothelial markers (CD31, Cdh5, Cldn5) and reduced the mRNA and protein levels of mesenchymal markers (α-SMA, FN1) in a dose-dependent manner.
Downregulated the protein expression of TGF-β1, p-Smad2, p-Smad3, and Smad4 in heart tissues in a dose-dependent manner.
Animal Model: C57BL/6 (male, 8-week-old)
Dosage: 25 mg/kg
Administration: i.p.; once daily; concurrent with cisplatin dosing cycles
Result: Mitigated cisplatin-induced increases in ABR hearing thresholds across 4, 8, 12, 16, 24, 32 kHz.
Significantly reduced cisplatin-induced elevations in DPOAE thresholds at 8, 12, 16, 24, 32 kHz, preserving outer hair cell function.
Increased cochlear hair cell counts per 100 μm in apex, middle, and base regions to levels matching or approaching control.
Reversed the >40% reduction in endocochlear potential (EP) caused by cisplatin, restoring EP values to near-control levels.
Downregulated cisplatin-induced overexpression of ferroptosis/ferritinophagy-related marker SOCS1 in cochlear tissue.
Reduced cisplatin-induced increases in NCOA4 protein expression while upregulating GPX4 and SLC7A11 protein expression.
Decreased cisplatin-induced co-localization of NCOA4 and LAMP1, and reduced cisplatin-induced autophagolysosome formation in cochlear cells.
Animal Model: Sprague Dawley (male, 8 weeks old, 180 g, partial abdominal aortic constriction-induced pressure overload)
Dosage: 2.5 mg/kg per day; 5 mg/kg per day; 7.5 mg/kg per day
Administration: i.p.; daily; 3 weeks
Result: Reduced heart weight/body weight ratio to 2.480 mg/g and left ventricular weight/heart weight ratio to 0.695 g/g (7.5 mg/kg dose, vs AAC vehicle group: 2.515 mg/g, 0.786 g/g).
Significantly reduced mRNA expression of hypertrophic biomarkers atrial natriuretic peptide and brain natriuretic peptide across all doses, with the most robust reduction at 7.5 mg/kg per day.
Reduced left ventricular collagen volume fraction and mRNA expression of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β across all doses compared to the AAC vehicle group.
Significantly inhibited AAC-induced increases in phosphorylated AKT, phosphorylated mTOR, and phosphorylated NF-κB p65 protein levels, while increasing IκB protein levels across all doses compared to the AAC vehicle group.
Animal Model: db/db (8-week-old, 35-40g, leptin receptor-deficient, spontaneous type 2 diabetes mellitus model with inherent cardiac fibrosis)
Dosage: 1 mg/kg; 2.5 mg/kg; 5 mg/kg
Administration: i.p.; daily; 8 weeks
Result: Significantly reduced interstitial and perivascular collagen fiber deposition in db/db mice, with a dose-dependent reduction in fibrosis area.
Dose-dependently reversed the elevated mRNA levels of fibrotic markers (Col1a1, Col3a1, Postn) in db/db mouse heart tissue.
Dose-dependently upregulated mRNA levels of endothelial markers (CD31, Cdh5, Cldn5) and downregulated mRNA levels of mesenchymal markers (α-SMA, FN1) in db/db mouse heart tissue, with corresponding changes in protein expression (α-SMA protein was dose-dependently reduced, and CD31 fluorescence intensity was dose-dependently increased via immunofluorescence).
Dose-dependently downregulated protein expression of TGF-β1, p-Smad2, p-Smad3, and Smad4 in db/db mouse heart tissue, with significant reductions in the ratios of TGF-β1/GAPDH, p-Smad2/t-Smad2, p-Smad3/t-Smad3, and Smad4/GAPDH observed at all doses, and the highest dose showing the strongest inhibitory effect.
Animal Model: C57BL/6J (male, 2 months old, 25-28 g, hindlimb unloading-induced osteoporosis model)
Dosage: 18 mg/kg; 36 mg/kg; 72 mg/kg
Administration: p.o.; daily; 21 days
Result: Reversed hindlimb unloading-induced reductions in femoral bone mineral density, trabecular bone volume fraction, trabecular bone mineral density, trabecular number, trabecular thickness, and cortical thickness, while decreasing trabecular separation relative to the untreated unloading group.
Significantly elevated mineral apposition rate compared to the untreated unloading group, with the 18 mg/kg dose showing the highest value.
Significantly increased maximum force and flexural strength relative to the untreated unloading group, with the 18 mg/kg dose showing the greatest improvement in flexural modulus.
At 18 mg/kg dose: Increased serum bone formation marker PINP, decreased serum bone resorption marker CTX-1, with levels not significantly different from normal control mice; significantly elevated femoral mRNA and protein levels of osteogenic markers Runx-2, OSX, and Col-I relative to the untreated unloading group; significantly increased the number of RUNX-2-positive cells on trabecular bone surfaces; significantly increased the number and area of ALP-stained bone marrow stromal cell colonies (CFU-F_ALP); significantly reduced the number of TUNEL-positive osteocytes in tibial cortical bone; significantly decreased serum levels of oxidative stress markers 8-isoPGF2α and 8-OHdG; significantly decreased serum levels of inflammatory cytokines IL-1β, IL-6, and TNF-α; significantly reduced femoral and serum RANKL/OPG ratios relative to the untreated unloading group.
Animal Model: Okamoto-Aobi strain spontaneous hypertensive rats (9-10 weeks old, 170-260 g, anesthetized)
Dosage: 30 mg/kg; 40 mg/kg; 100 mg/kg
Administration: i.v.; single dose
Result: Induced decreases in diastolic blood pressure of 25 mmHg and 35 mmHg in individual rats at 30 mg/kg.
Induced an 80 mmHg decrease in diastolic blood pressure at 40 mg/kg.
Induced decreases in diastolic blood pressure of 105 mmHg, 90 mmHg, 110 mmHg, and 120 mmHg in individual rats at 100 mg/kg.
Exhibited antihypertensive activity indistinguishable from the natural isolate from *Eucommia ulmoides*.
性状 固体
颜色 White to off-white

化学信息

分子量 682.67
分子式 C32H42O16
CAS No. 63902-38-5
别名 松脂醇二葡萄糖苷

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (14.65 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (4.83 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (146.48 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.4648 mL7.3242 mL14.6484 mL36.6209 mL
5 mM0.2930 mL1.4648 mL2.9297 mL7.3242 mL
10 mM0.1465 mL0.7324 mL1.4648 mL3.6621 mL
15 mM0.0977 mL0.4883 mL0.9766 mL2.4414 mL
20 mM0.0732 mL0.3662 mL0.7324 mL1.8310 mL
25 mM0.0586 mL0.2930 mL0.5859 mL1.4648 mL
30 mM0.0488 mL0.2441 mL0.4883 mL1.2207 mL
40 mM0.0366 mL0.1831 mL0.3662 mL0.9155 mL
50 mM0.0293 mL0.1465 mL0.2930 mL0.7324 mL
60 mM0.0244 mL0.1221 mL0.2441 mL0.6103 mL
80 mM0.0183 mL0.0916 mL0.1831 mL0.4578 mL
100 mM0.0146 mL0.0732 mL0.1465 mL0.3662 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础